Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
Nyxol
APX3330
APX2009
Posters and Publications
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Enrolling
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Last Patient Last Visit Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Presentations
News & Media
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Corporate Presentation
Ocuphire ZETA-1 Topline Results Conference Call Presentation
OIS XII, Retina Innovation Showcase
Ocuphire APX3330 KOL Event October 2022
OIS Retina 2022 - Mina Sooch
MIRA-3 Topline Results Conference Call Presentation
2022 Investor R&D Day Presentation
[email protected]
Presentation
VEGA-1 TopLine Data Results Conference Call Presentation
MIRA-2 Phase 3 Trial Results Conference Call Presentation
